Sabine D. Brookman-May

Interesting data from Phase 2 study #COMRADE at #ESMO26: Early on-treatment #ctDNA may help identify patients at risk of progression after just one cycle of #radium223. Possibly one more step toward biomarker-guided, adaptive radiopharmaceutical therapy.

We are getting more and more evidence about a potential key prognostic role of ctDNA also in #ProstateCancer including evidence that it may be used as a guide for treatment modulation - it will be most important now to prospectively include ctDNA in more trials and further validate it #mCRPC #RLT #Olaparib #radium223 @urotoday @oncodaily @OncoDailyGU @DrRanaMcKay

And confirmed again that #PSA Nadir (cut-off 0.2 l) is a strong prognostic factor and predictor of oncological outcomes OS, CRPC-FS in patients with #mAPMS PC.

A higher proportion of patients treated with ADT+ARPI compared to ADT+Docetaxel or ADT+D+ARPI achieved a deep PSA response - would be very interested in seeing the breakdown per treatment in both low and high volume categories, but I guess the nadir achieved reflects predominantly more aggressive disease rather than a treatment effect #ProstateCancer #UrologicOncology #PSANadir #Biomarkers @oncodaily @OncoDailyGU @urotoday @chavarriagaj

Positive DASL-HiCaP results presented at #ESMO26 @niazi_Dr7

👍Adding #darolutamide to ADT + RT in very-high-risk #ProstateCancer improved
✅4-year MFS (95% vs 88%; HR 0.42), ✅delayed CRPC (HR 0.22)
✅increased time to subsequent hormonal therapy (HR 0.36)

All clinically meaningful benefits, while OS remains immature.

#ProstateCancer #Radiationtherapy #UrologicOncology @oncodaily @OncoDailyGU @urotoday @ChrisSweens1

Great to finally see the results of the #PROTEUS substudy comparing #perioperative Apa+ADT with the true SOC (RP w/o neoadjuvant treatment) - which should at least reduce some concerns related to the active comparator with ADT in the main study that didn’t reflect what we actually do as a standard in HR patients #ESMO26

Outcomes in all #endpoints significant improved
✅EFS: HR 0.38, 95% CI 0.26–0.55
✅MFS: HR 0.49, 95% CI 0.26–0.90
✅TT 1st Sub Rx: HR 0.29, 95% CI 0.20–0.43

The question remains which of these outcomes are most clinically relevant and meaningful #PROTEUS #ProstateCancer #UrologicOncology #Apalutamide #RadicalProstatectomy @oncodaily @OncoDailyGU @urotoday @Albert0Briganti @JNJInnovMed

Couldn’t agree more @niklas_kluemper
It is our responsibility as urologists to make sure that patients receive the most appropriate treatment and that we consider perioperative treatment with #EVP. Most of the patient patients eligible for #RadicalCystectomy will also be eligible for EVP #BladderCancer #UC #Urology @oncodaily @OncoDailyGU